LETTER to the EDITOR Salvage Chemotherapy with Weekly Paclitaxel for Metastatic Melanoma (Zimpfer-Rechner et al., 2003) . Paclitaxel has been evaluated in phase II trials in melanoma (Zimpfer-Rechner et al., 2003; Walker et al., 2005) . In a study of salvage therapy for metastatic melanoma among 27 patients, no patient responded with CR or PR and median PFS was found 1.8 months and median OS 7.6 months (Walker et al., 2005) . As second-line therapy, a randomized study of weekly paclitaxel versus carboplatin plus paclitaxel was stopped because the overall response rate was below 10% in both arms and there was no difference in time to progression and median survival between the two arms (Zimpfer-Rechner et al., 2003) . Paclitaxel with or without carboplatin had only limited efficacy as second-line therapy for metastatic melanoma. Even if new molecular-targeted therapy including vemurafenib, ipilimumab, MEK inhibitors, anti PD-1 and anti PD-L1 become effective and actual therapy modalities, they always should be set above the existing chemotherapy for salvage therapy of metastatic melanoma (Grimaldi et al., 2014; Mamalis et al., 2014) . 
